NCT00582855

Effect of AQW051 in Patients With Memory Impairment

A 4-week, Parallel-group, Randomized, Double-blind, Placebo-controlled, Adaptive Proof of Concept Study of AQW051 at up to Three Dose Levels for the Treatment of Patients With Findings Consistent With Mild Alzheimer's Disease (AD) or Amnestic Mild Cognitive Impairment (Amnestic MCI)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 55 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure cognitive function. This study will also explore the safety and tolerability of AQW051 in these patients.

Conditions

• Mild Alzheimer's Disease
• Amnestic Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	AQW051
DRUG	Placebo

Timeline

• Start date: 2007-12-01
• Primary completion: 2009-02-01
• First posted: 2007-12-28
• Last updated: 2016-04-19

Locations

12 sites across 3 countries: Canada, South Africa, United Kingdom